- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
Clinicaltrials.gov identifier NCT03942653
Recruitment Status Recruiting
First Posted May 8, 2019
Last update posted November 17, 2020
A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to surgery or radiation.
This is a Phase II multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to surgery or radiation. Eligible patients will include both those with no prior systemic therapy and those who have failed prior systemic therapy. Patients who have received previous ADT or immunotherapy will be excluded. ADT will consist of goserelin acetate every 4 weeks with the first injection given approximately 2 weeks prior to the first dose of pembrolizumab. Pembrolizumab 200 mg will be given on day 1 of 21-day cycles, starting 2 weeks after initiation of goserelin acetate. Each 21-day period is considered a treatment cycle with therapy continuing for up to 35 cycles, until disease progression, significant toxicity, or patient refusal. Except for fatigue, we do not expect overlapping toxicities with pembrolizumab and ADT, thus the starting doses will be the FDA-approved doses. This study will use a Simon 2-stage phase II trial design. The first stage of the Simon 2-stage design will have a sample size of nine patients. If at least two patients have an objective response by RECIST 1.1 then enrollment will proceed to stage 2 with an additional 11 patients, to a goal of 20 patients. If less than 4 patients out of 20 respond, then the combination treatment will be rejected. Patients will be staged with CT of neck, chest, abdomen, and pelvis at baseline and every 12 weeks while on study. Treatment with both ADT and pembrolizumab will continue until disease progression or intolerable side effects. Archival tumor biopsy tissue must be available at baseline to evaluate for expression of androgen receptor (AR), PD-L1, and tumor-infiltrating lymphocytes (TIL). An optional biopsy will be performed after 4 doses of pembrolizumab to evaluate immune response to combined therapy. Blood will be collected at baseline, cycle 1 day 1, cycle 2 day 1 and cycle 3 day 1 to evaluate for change in lymphocyte subsets by flow cytometry.
|Experimental: Goserelin Acetate + Pembrolizumab
Goserelin Acetate, 3.6 mg, every four weeks, SQ Pembrolizumab, 200mg, every three weeks, IV
Drug: Goserelin Acetate
Goserelin Acetate, SQ, Q4W
Pembrolizumab, IV, Q3W
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, , Learn About Clinical Studies.-->
- Written informed consent and HIPAA authorization for release of personal health
information. NOTE: HIPAA authorization may be included in the informed consent or
- Age ≥ 18 years at the time of consent.
- Locally advanced, recurrent, or metastatic salivary gland carcinoma that is not
amenable to curative surgery or radiation
- ECOG Performance Status of 0 or 1 within 28 days prior to registration.
- Local, pathologic testing of androgen receptor-positive salivary gland carcinoma will
be performed as standard of care. Archival tissue must be available for central
confirmation of androgen receptor-positive disease and for correlative studies. AR
positivity will be defined according to IHC staining of tumor tissue with at least 20%
of tumor staining positive with moderate intensity (1+ or greater).
- Measurable disease according to RECIST v1.1 for solid tumors within 28 days prior to
- For patients who have been treated with prior therapy, patients must have documented
progression of disease on their prior therapy for entry into the study.
- Patients with prior chemotherapy, radiation, or surgery as part of curative intent
therapy are allowed. Any number of prior lines of systemic therapy is permitted for
entry into this study so long as prior therapy did not include anti-androgen therapy
or immune checkpoint blockade.
- If prior cancer treatment, the subject must have recovered from toxic effects of prior
cancer treatment (other than alopecia) to ≤ Grade 1.
- Adequate organ function as defined below; all screening labs to be obtained within 28
days prior to registration.
- Absolute neutrophil count (ANC) ≥1500/µL
- Platelets ≥75,000/µL
- Hemoglobin ≥8.0 g/dL or ≥5 mmol/L
- Creatinine (Cr) OR Measured or calculated creatinine clearance (GFR can also be
used in place of Cr or creatinine clearance) ≤1.5 × ULN OR
≥30 mL/min for participant with creatinine levels >1.5 × institutional ULN
- Total bilirubin ≤1.5 ×ULN OR direct bilirubin ≤ULN for participants with total
bilirubin levels >1.5 × ULN
- AST (SGOT) and ALT (SGPT) ≤2.5 × ULN (≤5 × ULN for participants with liver
metastases) o International normalized ratio (INR) OR prothrombin time (PT) &
aPTT ≤1.5 × ULN unless participant is receiving anticoagulant therapy as long as
PT or aPTT is within therapeutic range of intended use of anticoagulants
- A male participant must agree to use contraception during the treatment period and for
at least 8 months after the last dose of study treatment and refrain from donating
sperm during this period.
- Females of childbearing potential must have a negative serum pregnancy test within 72
hours prior to registration. NOTE: Females are considered of child bearing potential
unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal
ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least
12 consecutive months
- Females of childbearing potential and males with partners of childbearing potential
must be willing to abstain from heterosexual activity or to use a highly effect form
of contraception from the time of informed consent until 8 months after treatment
- As determined by the enrolling physician or protocol designee, ability of the subject
to understand and comply with study procedures for the entire length of the study
- Women of childbearing age with a positive serum pregnancy test within 72 hours prior
to study registration.
- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with
an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4,
- Has received prior androgen deprivation therapy including orchiectomy,
gonadotropin-releasing hormone (GnRH) agonists/antagonists, androgen receptor blocker,
abiraterone, or enzalutamide.
- Has received prior systemic anti-cancer therapy including investigational agents
within 14 days prior to registration.
- Has received prior palliative radiotherapy within 7 days of start of study treatment.
Participants must have recovered from all radiation-related toxicities and require
less than 10mg of prednisone (or equivalent corticosteroid) daily.
- Has received a live vaccine within 28 days prior to the first dose of study drug.
Examples of live vaccines include, but are not limited to, the following: measles,
mumps, rubella (MMR), varicella/zoster (chicken pox), yellow fever, rabies, Bacillus
Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection
are generally killed virus vaccines and are allowed; however, intranasal influenza
vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
(in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days prior to the first dose of study drug.
- Has a known additional malignancy that is progressing or has required active treatment
within the past 2 years. Note: Participants with basal cell carcinoma of the skin,
squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast ductal
carcinoma in situ, cervical cancer in situ) that have undergone potentially curative
therapy are not excluded.
- Has known active CNS metastases and/or carcinomatous meningitis. Participants with
previously treated brain metastases may participate provided they are radiologically
stable, i.e. without evidence of progression for at least 14 days by repeat imaging
(note that the repeat imaging should be performed during study screening), clinically
stable, and without requirement of steroid treatment for at least 14 days prior to
first dose of study treatment.
- Has ≥Grade 3 hypersensitivity to pembrolizumab and/or any of its excipients.
- Has active autoimmune disease that has required systemic treatment in the past 2 years
(i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
drugs). Replacement therapy (eg, levothyroxine, insulin, or physiologic corticosteroid
replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
form of systemic treatment.
- Has a history of (non-infectious) pneumonitis that required steroids or has current
- Has an active infection requiring systemic therapy.
- Has a known history of Human Immunodeficiency Virus (HIV).
- Has a known history of active TB (Bacillus Tuberculosis).
- Has a history or current evidence of any condition, therapy, or laboratory abnormality
that might confound the results of the study, interfere with the subject's
participation for the full duration of the study, or is not in the best interest of
the subject to participate, in the opinion of the treating investigator.
- Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial.
- Is pregnant or breastfeeding or expecting to conceive or father children within the
projected duration of the study, starting with the screening visit through 120 days
after the last dose of trial treatment.
Contact: Manish Patel, MD 6126246940 Patel069@umn.edu
Contact: Julia Beck 3176345842 ext 62 firstname.lastname@example.org
United States, Illinois
Northwestern University Feinberg School of Medicine
United States, Illinois
University of Illinois Cancer Center
United States, Iowa
University of Iowa Hospitals and Clinics
United States, Michigan
University of Michigan Health System
United States, Minnesota
University of Minnesota: Masonic Cancer Center
United States, Wisconsin
University of Wisconsin
Merck Sharp & Dohme Corp.
Principal Investigator: Manish Patel University of Minnesota